Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study

Authors
Category Primary study
JournalEuropean Neuropsychopharmacology
Year 2019
This article has no abstract
Epistemonikos ID: 99cac9df949a0c8a61ca99689e757f5008fc9671
First added on: Feb 10, 2025